What this means
This is a plan for a study that will test a daily 60 mg dose of Dermial against a placebo for 12 weeks. No results have been posted, so we do not yet know if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 35–65 · Healthy women aged 35 to 65, study not yet reported
- Where
- 1 site
The science
- Registered title
- Clinical Study to Evaluate the Anti-aging Efficacy and Skin Radiance-enhancing Effect of Dermial®.
- Trial ID
- NCT07790237 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Healthy Adult Females
- What is tested
- DERMIAL, Placebo
- Sponsor
- Bioiberica
- Ages
- 35 Years to 65 Years
- Dates
- First posted Aug 27, 2026 · updated Sep 18, 2026
Registry summary
The present clinical study has been designed to evaluate the efficacy and safety of Dermial® at a daily dose of 60 mg on skin brightness, hydration, luminosity and other signs of facial skin aging in healthy women aged 35 to 65 years presenting physiological age-related skin aging, compared with placebo over a 12-week supplementation period.
Sites (1)
- Institute of Advanced Medicine and Dermatology (IMDA), Madrid, Madrid, Spain